Adherence to ribavirin is one factor that is critically important in the treatment of hepatitis C virus infection. However, ribavirin can be associated with clinically significant hemolytic anemia resulting in dose modifications in up to one-quarter of patients. Currently, baseline predictors of considerable anemia are not sufficiently discriminating for routine therapeutic intervention. The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4.
METHODS:
Multivariate logistic regression analysis was used to explore possible predictors for considerable hemoglobin decline (≥2.5 g/dL) at week 4 among patients receiving peginterferon alfa-2a (40KD) and ribavirin (1,000/1,200 mg/day).
RESULTS:
A total of 555 patients were included in this analysis. At week 4, 236 patients exhibited a ≥2.5 g/dL decrease in hemoglobin. By regression analysis the most important independent variables associated with a decrease in hemoglobin of ≥2.5 g/dL were baseline creatinine clearance (P = 0.0003) and a rapid decline in hemoglobin of ≥1.5 g/dL at week 2 (P < 0.0001). Considerable hemoglobin decreases at week 4 were also significantly associated with early ribavirin dose reductions and a lower cumulative daily dose of ribavirin.
CONCLUSION:
Patients with impaired renal function may be at an increased risk of ribavirin-related anemia and should be monitored accordingly. Furthermore, a hemoglobin drop of ≥1.5 g/dL by week 2 was an excellent early predictor for subsequent considerable hemoglobin decreases and might be used to identify candidates for early intervention against anemia in order to help maintain ribavirin dosing and avoid suboptimal exposure.
(Am J Gastroenterol 2008;103:1981-1988)
BACKGROUND
As many as 5 million Americans have been exposed to hepatitis C virus (HCV) and the majority will go on to develop chronic infection. Individuals with chronic hepatitis C infection are at risk for serious complications-for example, HCV is the principal cause of hepatocellular carcinoma, the major indication for liver transplantation-and HCV directly contributes to an estimated 13,000 deaths in the United States annually. The combination of peginterferon and ribavirin can achieve sustained virologic response (SVR; HCV RNA <50 IU/mL 24 wk after treatment) in over 50% of those treated (1, 2) . However, soon after the introduction of peginterferon and ribavirin, it was recognized that adherence to treatment is critical to maintaining high rates of virologic clearance (3). Unfortunately, peginterferon plus ribavirin therapy can be associated with side effects, some of which may lead to dose reductions, premature discontinuation of the drug, and subsequent treatment failure (4). As recently reviewed by McHutchison et al., ribavirin is associated with dose-dependent hemolytic anemia, which occurs in a considerable proportion of treated patients (4) with reductions in hemoglobin reaching a nadir after approximately 4 wk of treatment (5) . Although treatment-related side effects can make therapy unpleasant, most do not lead to disruption or discontinuation of therapy. However, hemolytic anemia associated with ribavirin frequently leads to ribavirin dose reductions. Indeed, in a peginterferon alfa-2a pivotal trial, it was reported that patients receiving peginterferon alfa-2a plus ribavirin had a median maximal decrease in hemoglobin of 3.7 g/dL, and this resulted in a ribavirin dose modification in 22% of patients (1) . High rates of anemia are not unique to that study; retrospective analyses of patients receiving combination therapy with ribavirin and interferon alfa-2b confirm the frequent occurrence of anemia. In one study, more than 50% of patients experienced a decrease in hemoglobin of ≥3.0 g/dL (6) , and, in another study, by 4 wk of treatment ribavirin dose reduction was required in 12.2% of patients increasing to 27.6% of patients by 24 wk, with a mean maximal decrease in hemoglobin of 4.0 g/dL (7) .
Although these studies suggest that multiple baseline factors may predict an increased risk of significant anemia, no analysis is sufficiently discriminating to justify therapeutic intervention. Following a prior analysis of 58 HCV genotype 1 (HCV-1) patients, a significant correlation was found between a decrease in hemoglobin of ≥1.5 g/dL from baseline to week 2 (rapid hemoglobin reduction, RHR) and a week-4 hemoglobin decline of ≥2.5 g/dL-a decline that may be clinically significant in many patients (8) . Therefore, using this time point, the objective of the present analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4.
METHODS

Study Design and Patients
Data from two pivotal, prospective, randomized, international phase III trials in treatment-naive adults with HCV-1 infection were pooled for this post hoc analysis (1, 9) . The objective was to evaluate baseline and on-treatment characteristics with the potential to predict considerable hemoglobin decreases (≥2.5 g/dL decrease in hemoglobin from baseline), and hence identifying patients at an increased risk of anemia at treatment week 4. A hemoglobin decline of 2.5 g/dL was selected as a marker of potential clinically relevant anemia as this approximated the median decline in the overall population and allowed a sufficient number of patients to explore factors associated with this magnitude of decline in hemoglobin.
The study design methodology and the main findings of the studies have been published elsewhere (1, 9) . Briefly, the studies recruited patients with anti-HCV antibodies, quantifiable HCV RNA (>600 IU/mL via COBAS Amplicor HCV Monitor Test, V2.0; Roche Diagnostics, Branchburg, NJ), increased serum alanine aminotransferase (ALT), and wellcompensated liver disease. Liver biopsy findings were consistent with chronic hepatitis C. Patients were excluded with baseline neutropenia (neutrophil count <1.5 × 10 9 cells/L), thrombocytopenia (platelet count <90 × 10 9 cells/L), anemia (hemoglobin level <12 g/dL in women and <13 g/dL in men), HIV, hepatitis A or hepatitis B coinfection, decompensated liver disease, a serum creatinine level >1.5 times the upper limit of normal, poorly controlled psychiatric disease, recent alcohol or drug dependence, or substantial coexisting medical conditions.
Only genotype 1 patients randomized to 48 wk of treatment with subcutaneous peginterferon alfa-2a (40KD) (PE-GASYS; Roche, Basel, Switzerland) 180 µg once weekly plus oral ribavirin (COPEGUS; Roche) were included in this analysis. Furthermore, in this subset, only patients who received at least one dose of study drug and had hemoglobin assessments before treatment and at week 4 during treatment were subsequently included.
Anemia Assessments
Anemia assessments (serum hemoglobin) were obtained at baseline and weeks 1, 2, 4, 6, 8, and 12, and at 6-wk intervals thereafter, in one trial (9) , and at baseline and weeks 1, 2, 4, 6, and 8, and at monthly intervals thereafter including weeks 52, 60, and 72, in a second trial (1) . Dose modification occurred per protocol: ribavirin was reduced to 800 mg/day (9) or to 600 mg/day (1) if the hemoglobin level dropped below 10 g/dL in patients without heart disease or decreased by ≥2 g/dL in patients with stable heart disease. Ribavirin was discontinued if hemoglobin fell below 8.5 g/dL.
Efficacy and Safety End Points
The primary efficacy end point for both studies was SVR, defined as undetectable serum HCV RNA (<50 IU/mL) by qualitative polymerase chain reaction (COBAS Amplicor HCV Monitor Test, V2.0) at the end of a 24-wk untreated follow-up phase. Post hoc analysis for creatinine clearance was calculated according to the Cockcroft and Gault equation using data obtained during baseline laboratory testing.
The percentage of premature withdrawals, the percentage of patients with dose reductions as a result of anemia, the mean treatment duration, the cumulative dose, and the average dose of peginterferon alfa-2a (40KD) and ribavirin were determined for patients with and without a 2.5 g/dL decline in hemoglobin at week 4.
Statistical Analysis
Various baseline and on-treatment characteristics, as well as SVR, in patients with and without hemoglobin declines (≥2.5 g/dL) at week 4 were compared using the chi-squared test for association in the case of categorical data or the Student's t-test in the case of continuous data. Univariate and multivariate logistic regression analyses were used to assess the association between several possible predictors and hemoglobin decreases at week 4. Characteristics included are gender, race, age, mode of HCV transmission, body weight, body mass index, fibrosis/cirrhosis status, genotype subtype, HCV RNA titer, geographical region, hemoglobin, platelet and white blood cell counts, creatinine level, creatinine clearance, ribavirin start dose per kg of body weight, cumulative dose of ribavirin and peginterferon alfa-2a (40KD) per kg of body weight in the first 4 wk, and achieving an RHR (week 2 hemoglobin reduction of ≥1.5 g/dL from baseline).
In the stepwise model building process of the multivariate logistic regression analysis, a variable was added to the model if the adjusted chi-square statistic was significant at the 0.1 level and a variable was deleted from the model if the Wald chi-square statistic was not significant at the 0.05 level. For the resulting independent predictive factors, odds ratio and 95% confidence intervals (CI) were calculated. The functional association of continuous variables with considerable anemia was examined by generalized additive logistic regression models.
RESULTS
Five hundred fifty-five patients fulfilled the criteria for analysis (Fig. 1) ; 236 patients (42.5%) exhibited considerable hemoglobin decreases, defined as a drop of ≥2.5 g/dL at week 4. In these patients the median decrease at week 4 was 3.4 g/dL, with a range of 2.5-7.4 and interquartile range of 2.9-4.1. Baseline characteristics for both groups were compared (Table 1) .
Using univariate regression analysis, several factors were predictive factors for considerable hemoglobin decrease at week 4 ( Hadziyannis 2004) (1, 9) . Hb = hemoglobin. Eleven patients were excluded from the logistic regression analyses because of missing data in at least one of the analyzed factors.
weight in the first 4 wk was excluded from the final multivariate logistic regression analysis because the observed lower ribavirin dose in the first 4 wk in patients with a considerable hemoglobin decrease seems to be a reaction to the developing anemia and cannot be used as an explanation for more pronounced anemia.
Plotting baseline creatinine clearance against hemoglobin reductions of ≥2.5 g/dL at week 4 ( Fig. 2A) shows that, as baseline creatinine clearance increases, the probability of hemoglobin reductions of ≥2.5 g/dL at week 4 decreases continuously across the entire range. This highlights the potential heightened risk of anemia in patients with impaired renal function at baseline.
The factor most strongly associated with considerable hemoglobin reductions at week 4 in the multivariate logistic regression analysis was achieving an RHR. This is illustrated in Figure 2B , which shows that 84% of patients with a week-2 reduction of hemoglobin of ≥1.5 g/dL subsequently experienced more significant week-4 decreases (≥2.5 g/dL decrease from baseline) compared with only 18% of patients with a week-2 reduction of hemoglobin of <1.5 g/dL (P < 0.0001). While this might be what one would expect, it confirms that relatively small hemoglobin declines at week 2 progress to more significant declines after a further 2 wk of treatment. 
Treatment Adequacy
On-treatment characteristics of patients with and without week-4 hemoglobin drops of ≥2.5 g/dL in the two studies (Table 3) showed that these week-4 decreases significantly correlated with more and earlier ribavirin dose reductions as a result of anemia (P < 0.0001), and thus a lower cumulative and average daily dose of ribavirin (P = 0.0005 and P < 0.0001, respectively). Furthermore, patients with hemoglobin declines of ≥2.5 g/dL at week 4 were significantly more likely to have their dose of ribavirin reduced, resulting in receiving <60% of the target dose compared with patients with smaller declines in hemoglobin (30.1% vs 21.6%; P = 0.0234, respectively). There was no corre- RHR = rapid hemoglobin reduction (≥1.5 g/dL decrease in hemoglobin at week 2 from baseline). * Eleven patients were excluded from the logistic regression analyses as a result of missing data in at least one of the analyzed factors. Explanatory factors with a P-value > 0.1 in the univariate analysis are not listed in Table 2 . † For discrete variables, the odds ratio is the ratio of the odds of the first category versus the opposite category. ‡ For continuous variables, the odds ratio relates to a unit change as specified (e.g., the odds of having a hemoglobin drop of ≥2.5 g/dL at week 4 in a patient with baseline hemoglobin of 11 g/dL is 34% higher than in a patient with baseline hemoglobin of 10 g/dL; odds ratio 1.34).
lation with cumulative peginterferon dose, mean treatment duration, or completion of treatment course.
Treatment Efficacy
Despite significantly greater reductions in ribavirin exposure, the likelihood of SVR in patients with considerable hemoglobin decreases at week 4 was only slightly lower than that in patients without such decreases, a difference that was not found to be statistically significant (47.5% vs 51.7%; P = 0.3203). However, when hemoglobin drop at week 2 was plotted as a continuous variable against the probability of achieving an SVR, it was evident that across the range of observed drops in hemoglobin at week 2, a relationship with the probability of achieving an SVR was clearly present (Fig. 3) . A similar relationship was also seen when hemoglobin drop at week 4 was plotted as a continuous variable against the probability of achieving an SVR (data not shown). 
DISCUSSION
This study demonstrates that considerable and potentially clinically significant decreases in hemoglobin from baseline can be predicted by a decrease in hemoglobin of ≥1.5 g/dL after only 2 wk of therapy (RHR). This may provide clinicians with an early opportunity to evaluate the pros and cons of reducing the dose of ribavirin in patients at a high risk of developing anemia, or to consider the later use of hematological growth factors to treat ribavirin-associated anemia thereby enabling patients to maintain their ribavirin exposure. Early indicators of subsequent considerable anemia should prompt the physician to primarily consider early and small reductions in ribavirin dose (200 mg decrements) to reduce the risk of considerable anemia while maintaining adequate exposure to ribavirin. In addition, recent trials have demonstrated that higher starting doses of ribavirin can improve SVR rates in difficult-to-treat populations (10) (11) (12) , making the early identification of patients at risk of significant hemoglobin reductions increasingly important. Growth factors may be considered as an adjunct to dose reduction but should be used at the lowest dose to gradually increase hemoglobin concentrations to the lowest level sufficient to maintain ribavirin dosing (13) .
In our analysis we identified several independent baseline factors predictive of considerable hemoglobin decreases at week 4, allowing physicians the opportunity to identify patients at heightened risk of developing anemia even before starting therapy (Table 2) . Our findings confirm other recent reports of predictors of anemia. Although Spangler and colleagues found no baseline predictors of ribavirin-associated anemia in a small study of 58 patients infected with HCV-1, they did show that 81% of patients with a ≥1.5 g/dL drop in hemoglobin at week 2 had considerable anemia at week 4 compared with only 18% of patients with a <1.5 g/dL hemoglobin drop at week 2 (P < 0.001) (8) . These finding are remarkably similar to those of our own.
In a different analysis based upon a generalized additive logistic model, the probability of anemia has been calculated to increase from 6% to 16% as a function of ribavirin dose (from 12 mg/kg/day to 16 mg/kg/day) (14) . Our results and those of others clearly show that anemia is a common and significant problem during treatment with interferon and ribavirin. A decline in hemoglobin begins shortly after initiation of treatment and generally reaches the lowest level after 4-6 wk of therapy (5, 7, 15) . Indeed, treatment-induced anemia has been shown to be one of the most frequently reported adverse events in pivotal trials and contributes to dose reductions and treatment discontinuations (1, 2, 5, 7, 9, (16) (17) (18) (19) .
Although anemia is reversible when therapy is discontinued, it has potential impact on treatment outcome in relation to adequate ribavirin dosing. Compared with interferon or peginterferon monotherapy, the combination of interferon and ribavirin greatly increased the rate of SVR and decreased the risk of relapse after discontinuation of therapy (1, 2) .
Certainly, ribavirin is not the only cause of treatmentrelated anemia, as interferon has been shown to suppress bone marrow hematopoiesis (20) , and erythropoietin production is blunted in patients with anemia receiving peginterferon and ribavirin (21) . However, it has been suggested that higher exposure to ribavirin (15 mg/kg) may improve treatment efficacy, especially by decreasing the risk of relapse although this approach is anticipated to have a higher association with anemia (14, 22) .
In our analysis, while the rate of SVR among those patients with hemoglobin decreases ≥2.5 g/dL was similar to that among patients without such decreases, it was shown that across the whole range of hemoglobin drops, either at week 2 or week 4, greater decreases in hemoglobin were associated with a lower probability of achieving an SVR. Consequently, the failure to show a significant reduction in SVR in our analysis may be explained by dichotomizing the population at hemoglobin decreases of ≥2.5 g/dL and those with smaller decreases in hemoglobin.
In conclusion, although associated with anemia, ribavirin is a critical component to the successful treatment of HCV. To maintain the highest likelihood of achieving an SVR the dose of ribavirin should be initiated at the highest appropriate dose and maintained for as long as possible. In our analysis, achieving an RHR (decline in hemoglobin of ≥1.5 g/dL at week 2) was a reliable predictor of greater and potentially clinically relevant decreases in hemoglobin later in the course of peginterferon and ribavirin therapy and provides an early indication that the dose of ribavirin may need to be modified. However, when warranted, the dose of ribavirin should be reduced by the smallest decrement possible (200 mg), avoiding reduction to ≤60% of the target dose because this is known to be associated with a significant reduction in the rate of SVR.
